Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 23Leukemia 3Recurrence 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Higher-risk Myelodysplastic Syndrome 1Hematologic Diseases 1Dendritic Cell Sarcoma, Interdigitating 1Bone Marrow Diseases 1

Interventions

polatuzumab vedotin 2glofitamab 2Prednisone 2Doxorubicin 2Cyclophosphamide 2relmacabtagene autoleucel 1obinutuzumab 1axicabtagene ciloleucel 1Rituximab 1Oxaliplatin 1Gemcitabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Dendritic Cell Sarcoma, Interdigitating × Azacitidine × Clear all
NCT06778902 2025-01-16

Dragon

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 2 Not yet recruiting
80 enrolled
LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡